AbbVie: Upadacitinib (RINVOQ) Achieved Primary and Key Secondary Endpoints in First Phase 3 Induction Study in Patients with Crohn's Disease

Press/Media

Period6 Dec 2021

Media coverage

1

Media coverage

  • TitleAbbVie: Upadacitinib (RINVOQ) Achieved Primary and Key Secondary Endpoints in First Phase 3 Induction Study in Patients with Crohn's Disease
    Media name/outletIndia Pharma News
    Country/TerritoryIndia
    Date6/12/21
    PersonsJean-Frédéric Colombel
View all 1
View less